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ABSTRACT
Interactionswithco-factorsprovideameansbywhich
HOX proteins exert specificity. To identify candidate
protein interactors of HOXA13, we created and
screened an E11.5–E12.5, distal limb bud yeast two-
hybrid prey library. Among the interactors, we
isolated the BMP-signaling effector Smad5, which
interacted with the paralogous HOXD13 but not with
HOXA11 or HOXA9, revealing unique interaction
capabilities of the AbdB-like HOX proteins. Using
deletionmutants,wedeterminedthattheMH2domain
ofSmad5isnecessaryforHOXA13interaction.Thisis
the first report demonstrating an interaction between
HOX proteins and the MH2 domain of Smad proteins.
HOXA13andHOXD13alsobindtootherBMPandTGF-
b/Activin-regulated Smad proteins including Smad1
and Smad2, but not Smad4. Furthermore, HOXD13
could be co-immunoprecipitated with Smad1 from
cells. Expression of HOXA13, HOXD13 or a HOXD13
homeodomain mutant (HOXD13
IQN.AAA) antagonized
TGF-b-stimulated transcriptional activation of the
pAdtrack-3TP-Lux reporter vector in Mv1Lu cells as
well as the Smad3/Smad4-activated pTRS6-E1b
promoter in Hep3B cells. Finally, using mammalian
one-hybridassay,weshowthattranscriptionalactiva-
tion by a GAL4/Smad3-C-terminus fusion protein is
specifically inhibited by HOXA13. Our results identify
a new co-factor for HOX group 13 proteins and sug-
gestthatHOXproteinsmaymodulateSmad-mediated
transcriptional activity through protein–protein
interactions without the requirement for HOX
monomeric DNA-binding capability.
INTRODUCTION
Mammals have 39 Hox genes that encode transcription factors
that are essential for normal development (1). Mutations in
group 13 HOX genes have been described in the human
HOXA13 and HOXD13 genes, and engineered and spontan-
eous mutants of both genes have added signiﬁcantly to our
understanding of their role in development (2–15). However,
our knowledge of how these proteins gain speciﬁcity of
function in different tissues is limited.
One mechanism whereby HOX proteins achieve functional
speciﬁcity is by interaction with additional DNA-binding
co-factors, of which PBX and MEIS proteins to date are the
most studied (16). PBX proteins interact cooperatively on
DNA with HOX proteins of paralog groups 1–10 but not
groups 11–13 (17,18),while MEIS proteins cooperativelybind
to DNA with paralog groups 9–13 (19). Interactions have also
been demonstrated to occur between MEIS proteins and
HOXA13 and HOXD13, as well as non-AbdB-like HOX pro-
teins in the absence of DNA (20). However, in the developing
limb bud mesenchyme Meis1-3 are expressed in a separate
more proximal region than the distally restricted expression of
Hoxa13 and Hoxd13 (20–22), thus precluding a productive
interaction.
We sought to identify potential co-factors of HOXA13
using a yeast two-hybrid screen of a developmentally appro-
priate limb bud cDNA library. Among the isolated candidates,
we found Smad5, a well-described mediator of BMP function
(23,24) and a critical gene for embryonic and extra-embryonic
vascular development (25,26). Owing to the importance of
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doi:10.1093/nar/gki761Hoxa13 in limb, genitourinary tract, umbilical artery and
digestive tract development, we chose to analyze HOXA13/
Smad interactions and function in detail.
MATERIALS AND METHODS
Limb bud yeast two-hybrid cDNA prey library
Forelimb and hindlimb bud autopods of 140 C57BL/6J
embryos were harvested between E11.5 and E12.5, stages
4–10 (27). Total cellular RNA was puriﬁed using Trizol
reagent (Invitrogen Corporation). From 886 mg of total auto-
pod RNA, 5.9 mg of poly(A) RNA was obtained using the
Oligotex mRNA midi kit (Qiagen). Random-primed cDNAs
were created using the SuperScript Choice System (Invitrogen
Corporation) with EcoRI adapters and were ligated into the
EcoRI site of the prey vector pJG4-5 (Origene Technologies).
DNA from ligations was transformed into electrocompetent
DH10B cells (Invitrogen Corporation) producing 1.8 million
insert containing colony forming units (CFUs). Prey vector
DNA from pooled colonies was transformed into the haploid
yeast EGY188 (MATa) following the DupLEX-A large-scale
library transformation protocol. A total of 85 transformations,
each using 1 mg of DNA, were performed. Transformants were
selected on YNB (glucose) medium lacking tryptophan (trp).
Aliquots containing 3.6 · 10
6 yeast CFUs were pooled for use
in screening. Using dilution plating onto YNB (glucose)
medium lacking tryptophan, we estimated the pooled library
titer to be 6.6 · 108 CFU/100 ml.
Two-hybrid library screening
A HOXA13 bait construct was created by cloning the coding
sequence for amino acids 150–360 into the vector
pEG202NLS, placing the coding sequence 30 of the LexA
DNA-binding domain (DBD) and nuclear localization signal
(NLS). Bait plasmids and the lacZ reporter vector (pSH18-34)
weretransformedintothehaploidyeaststrainEGY40(MATa)
and transformants were selected for growth on YNB (glucose)
medium lacking histidine (his) and uracil (ura). The limb bud
prey library was screened using interaction mating (28,29).
Aliquots containing 3 · 10
8 CFUs were mated to the opposite
matingtypeanddiploidinteractorswereselectedforgrowthon
YNB(galactose)-his-ura-trp-leumedium.Baitautoactivation
potential was calculated as the ratio of colonies growing on
YNB (galactose) -his -ura -trp -leu versus -his -ura -trp (+leu).
The ratio was used to determine the number of interactors to
be screened based on the product of the bait autoactivation
potential and the number of unique preys in the prey library
(28).ThecalculatedCFUfromthebait/preylibrarymatingwas
replica plated on both YNB (galactose) -his -ura -trp +X-gal
and YNB (glucose) -his -ura -trp +X-gal medium. Those turn-
ing blue only on the galactose containing plates (prey protein
expressed)werecharacterizedfurther.Preyplasmidswereisol-
ated from diploid yeast following the DupLEX-A protocol and
sequenced using the 50 target fusion primer: 50-CTGAGTG-
GAGATGCCTCC-30. Candidate identiﬁcation was performed
using BlastN analysis of insert DNA sequence and BlastP
analysis of open reading frames (30).
Additional yeast two-hybrid preys were created by cloning
selected coding sequences into the prey vector pJG4-5, on the
30 end of the B42 transcriptional activation domain (AD), and
bait constructs were made by cloning coding sequences 30 of
the LexA DBD of the vectors pEG202 or pEG202NLS
(includes NLS). The speciﬁcity of interaction was assessed
for Smad5 and other preys by transformation of haploid
yeast strain EGY48 (MATa) followed by interaction mating.
Constructed bait vectors, pRFHMI (Bicoid HD), pBait
(TGFbRI), pSH17-4 (LexA DBD-GAL4 AD), pEG202
(LexA DBD) and pEG202NLS (LexA DBD-NLS) were each
cotransformed into the haploid yeast strain RFY206 (MATa)
with lacZ reporter vector (pSH17-4). Interaction mating and
visual scoring was performed 24 h after growth at 30 Co n
glucose and galactose medium (-trp, -his, -ura) with X-gal.
Sequence analysis
Accession numbers for the Mus musculus protein sequences:
HOXA13 (NP_032290), HOXD13 (NP_032301), Smad1
(AAG41407), Smad2 (AAH21342), Smad3 (NP_058049),
Smad4 (NP_032566), Smad5 (NP_032567), Smad6
(NP_032568), Smad7 (CAA04182) and Smad8 (AAF77079).
The accession numbers for Drosophila melanogaster are Mad
(AAB60230) and Medea (AAC38971). Comparison of protein
sequences was carried out using the MEGALIGN program
(DNASTAR) with the CLUSTAL W alignment algorithm
(31). A neighbor-joining tree was generated in MEGALIGN,
from the CLUSTAL W sequence alignments of full-length
protein sequences.
Plasmids
pAdtrack-3TP-Lux (32), pTRS6-E1b-luc (33,34) and pG5B-
luc (33) luciferase reporter plasmids have been described pre-
viously. Brieﬂy, 3TP-Lux is a chimeric reporter that contains
promoter elements of the human collagenase and PAI-1 genes
(35). This reporter is activated by TGF-b stimulation in a
variety of cells. The pTRS6-E1b-luc promoter is composed
of six copies of the  732/ 721 Smad3/Smad4 binding seg-
ment of the human PAI-1 promoter upstream of the E1bTATA
box in pE1b-luc (34). pG5B-luc has ﬁve copies of the GAL4
DNA-binding site upstream of the E1bTATA box in pE1b-
luc (33). Transfection controls included either Renilla
luciferase or chicken b-actin-promoter-b-galactosidase.
pCMV5-Hoxa13, pCMV5-Hoxd13, pCMV5-Hoxd13
IQN>AAA,
pCMV5-Hoxa9 and pCMV5-Hoxd11 encode full-length
cDNAs for each mouse gene. Negative control plasmids are
pCMV5 (empty vector), pPAI-RBP1 [pCMV backbone driv-
ing plasminogen activator inhibitor RNA-binding protein 1
(36)] and p37-AUF1 (a pCMV vector driving expression
of AUF RNA-binding protein) (a kind gift from Robert
Schneider). GAL4-Smad3C has been described previously
(33) and expresses a GAL4 DBD fusion protein composed
of amino acids 172–425 (the C-terminal activation domain)
of human Smad3. GAL4-VP16 is the GAL4 DBD with a VP16
AD (33). N-terminal FLAG-epitope-tagged Smad1 expression
vector was used in conjunction with constitutively activated
BMP type IA receptor (ALK3) vector for Mv1Lu cell assays
with the 3TP-Lux reporter and these have been described
previously (37,38).
Co-immunoprecipitation
The day prior to transfection 325 000 C3H 10T1/2 cells were
seeded into 60 mm dishes (3 per transfection condition). Prior
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saline (PBS) and incubated with media lacking antibiotics.
Transfections were performed using the FuGENE 6 reagent
(Roche Applied Science). Cells were transfected with expres-
sion constructs as indicated in Figure 4. Aliquots containing
2 mg each for pCMV5-Hoxd13 and FLAG-Smad1 (37,38)
expression vectors and 200 ng of the constitutively activated
BMP type IA receptor (ALK3) were used for transfection.
Forty-eight hours post-transfection, cell lysates were prepared
by collecting cells from three 60 mm dishes with trypsin-
EDTA. For each condition, cells were pelleted and lysed in
1 ml cold RIPA lysis buffer (50 mM Tris, pH 8.0, 150 mM
NaCl, 10% glycerol, 1% NP40, 0.5% DOC and 0.1% SDS).
Mechanical disruption with a 21G needle and brief sonication
were used to ensure efﬁcient disruption of nuclei. Cellular
debris was pelleted by centrifugation at 10 000 g for 10 min
and lysates were used for IP with anti-FLAG M2 afﬁnity
gel following the manufacturer’s protocol (Sigma–Aldrich).
Proteins were separated by electrophoresis on 12% SDS–
polyacrylamide gel and transferred to nitrocellulose for west-
ern analysis. We used primary antibody dilutions of 1:10 000
for rabbit anti-HOXD13, 1:1000 for rabbit anti-Smad1
(Upstate Biotechnology), 1:1000 for mouse M2 anti-FLAG
(Stratagene) and 1:10 000 each for anti-rabbit and mouse
horseradish peroxidase-conjugated secondary antibodies
(Amersham Biosciences) in PBST with 5% Carnation nonfat
dry milk. Proteins were visualized using Supersignal chemi-
luminescent substrate (Pierce Biotechnology).
Cell culture, transfection and luciferase assays
C3H 10T1/2 (mouse embryonic ﬁbroblasts), mink Mv1Lu
cells (32) and Hep3B (human hepatoma) cells were main-
tained in DMEM supplemented with 10% fetal bovine
serum (FBS), 100 U/ml penicillin, 100 mg/ml streptomycin
and 2 mM L-glutamine (Invitrogen Corporation). All transfec-
tions were performed using FuGENE 6 in 6- or 12-well plates.
For Mv1Lu cells, the day prior to transfection 150 000 cells
were seeded into individual wells of 6-well plates and then
transfected with 25 ng of Renilla luciferase normalization
vector pRLSv40, 1 mg of the luciferase reporter vector
pAdtrack-3TP-Lux and 2 mg of either pCMV5, pCMV5-
Hoxa13, pCMV5-Hoxd13 or pCMV5-Hoxd13
IQN>AAA.
Twenty-four hours post-transfection, cells were washed
with PBS and then grown for an additional 24 h in serum
starvation medium (SSM) with either TGF-b1 or vehicle.
SSM consisted of DMEM with 0.2% FBS, 100 U/ml penicil-
lin, 100 mg/ml streptomycin and 2 mM L-glutamine. TGF-b
stimulation was performed using SSM supplemented with
recombinant human TGF-b1 (R & D Systems) at 100 pM
or vehicle (32,39). For these 3TP-Lux experiments, Renilla
luciferase was used as the transfection control. For experi-
ments with pTRS6-E1b-luc or in mammalian one-hybrid
assays with pG5B-luc in Hep3B cells chicken b-actin-
promoter-b-galactosidase activity was measured (Clontech)
as the transfection control. Sixteen hours after transfection,
the cells were treated with 50 pM TGF-b1 for 24 h. In control
experiments, dexamethasone inhibited TGF-b stimulation of
pTRS6-E1b-luc expression in Hep3B cells as expected (33)
(data not shown). Cell lysates were prepared for measurement
of luciferase activity according to the manufacturer’s protocol
(Promega Corporation) and readings were taken using a
Monolight 3010 (BD Biosciences PharMingen). All luciferase
readings were normalized to the transfection control readings.
The average of several experiments each performed in trip-
licate with 1 SD is presented as a percent of control TGF-b
stimulation over basal activity. Duplicate transfected samples
were analyzed by western blotting to verify and compare the
expression of HOX proteins (data not shown).
RESULTS
Construction and characterization of a mouse
limb bud prey library
We created a random-primed yeast two-hybrid prey library
from E11.5–12.5 C57BL/6J forelimb and hindlimb buds, a
tissue and time during development known to exhibit strong
Hoxa13 expression. A total of 1.8 million independent cDNA
inserts were obtained in the yeast two-hybrid prey vector
pJG4-5. We predicted that one-sixth of the inserts
(300 000), on average, would be in the correct orientation
and reading frame. Insert-spanning PCR of 50 random clones
showed the average insert length to be 824 bp with a range
between 100 and 1800 bp.
HOXA13 specifically interacts with Smad5
To identify candidate HOXA13-interacting proteins, we used
a bait molecule comprising murine HOXA13 amino acids
150–360 (full-length protein is 1–386) fused in-frame on
the C-terminus of the LexA DBD with an NLS. This bait
has been utilized elsewhere to study HOXA13 co-factor
interactions (20). An estimate was derived for the number
of colonies necessary to be analyzed to identify potential inter-
actions with molecules of low abundance in the limb bud prey
library. The preys from 162 colonies that could grow on
leucine-deﬁcient medium and were positive for lacZ activity
were isolated and sequenced. BlastN and BlastP were used to
identify genes and to determine whether the isolated preys
represented coding sequences in the correct reading frame.
Of those, 56 preys were reintroduced into yeast and 13 were
found to interact speciﬁcally with the HOXA13 150–360 bait
and not with the negative control baits encoding the Bicoid
homeodomain (HD), TGFbRI or the LexA DBD-NLS alone
(data not shown). In this paper, we present our data with one of
these speciﬁc interactors, the BMP-signaling effector Smad5,
and explore further the HOX/Smad range of interactions,
peptide domains and function.
The Smad5 prey isolated from the library encoded amino
acids 175 through 465 (full-length ¼ 1–465). This clone rep-
resented a large portion of the linker and the MH2 domain of
Smad5. We inserted this Smad5 coding sequence (175–465)
into the bait vector, pEG202, and tested for interaction with a
HOXA13 prey encoding amino acids 150–360. Reversal of the
bait/prey orientation did not alter the speciﬁc interactions
observed between HOXA13 and Smad5 (data not shown).
Interaction between Smad5 and paralog group
13 HOX proteins is not a general property
of all AbdB-like HOX proteins
To test whether paralogous and non-paralogous HOX proteins
could interact with Smad5, we created preys including amino
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and 1–245 of mouse HOXA9 (Figure 1) and tested them by
interaction mating with a bait containing amino acids 175–465
of Smad5. All HOX preys terminate at homeodomain residue
41 (41/60), similar to that of HOXA13 (150–360). All tested
HOX preys were shown to interact with a positive control bait
containing MEIS1A (20); however,only the group 13paralogs
could interact with Smad5 amino acids 175–465 (Figure 1).
Theoverall speciﬁcityof thisinteractionwasfurther supported
by the inability of any of the HOX preys to interact with either
the Bicoid (HD), TGFbR1 or the LexA DBD alone baits.
Group 10 and 12 HOX proteins were not tested, but the
data indicate that the interaction is not a general property
of all AbdB-like proteins.
HOXA13 interacts with the MH2 domain of Smad5
Previous studies showing binding between HOXC8 and
Smad1 identiﬁed two HOX-interacting domains, HID1 and
HID2, in Smad1 that were necessary for the interaction
(40,41). Our isolated Smad5 prey did not retain the homolog-
ous HID1 region and was truncated within the homologous
HID2 region, suggesting the possibility that HOXA13 inter-
action was mediated through different Smad5 amino acids.
To identify the Smad5 domain(s) mediating HOXA13 inter-
actions, additional prey constructs were tested (Figure 2).
Smad5 preys with amino acids 1–198 (includes conserved
MH1 domain, and both homologous HID1 and HID2 motifs),
146–198 (HID2 homologous region only) or 1–265, which
includes the MH1 domain, HID1 and HID2 homologous
domains and the adjacent C-terminal linker regions, failed
to interact with HOXA13. However, preys including Smad5
amino acids 146–465, 202–465 and 265–465, all of which
include the MH2 domain, could interact. These results dem-
onstrate that the C-terminal amino acids of Smad5 that include
the MH2 domain are sufﬁcient for HOXA13 interaction.
HOXA13 and HOXD13 interact with the MH2 domain
of other BMP and TGF-b/Activin-regulated Smad
proteins
BMP ligands stimulate their cognate receptors to activate
the receptor-regulated Smads (R-Smads) Smad1, Smad5 and
Smad8 (23,24,42). These activated R-Smads dimerize in the
cytoplasm with the common Smad, Smad4, and subsequently
translocate to the nucleus where they participate in the regu-
lation of gene expression in combination with other transcrip-
tional regulators. To determine whether other Smad proteins
are capable of interacting with HOXA13 and HOXD13, prey
vectors were created corresponding to the C-terminal MH2
domain regions for the BMP effector Smad1, TGF-b/Activin
effector Smad2, and the common dimerization partner of all
BMP and TGF-b/Activin regulated Smads, Smad4. Interac-
tions of comparable intensity were observed between the para-
log group 13 HOX proteins and both Smad1 and Smad2, but
not with Smad4 (Figure 3A). Interactions were not tested for
the inhibitory Smads (I-Smads), Smad6 and Smad7, as their
amino acid sequence identity in the respective C-terminal
MH2-containing domains is markedly lower (Figure 3B).
These experiments demonstrate that HOXA13 and HOXD13
are able to interact in yeast with receptor-regulated Smad
proteins downstream of both TGF-b/Activin and BMP path-
ways, but not with the common Smad, Smad4.
HOXD13 and Smad1 interact in cells
To determine whether full-length Smad proteins and a paralog
group13HOX proteinare capableofassociatinginthe context
Figure 1. HOXA13 and HOXD13 interact specifically with Smad5. Bait proteins were tested for interaction with the HOX paralog group 13 proteins, HOXA13
(amino acids 150–360) and HOXD13 (amino acids 1–312) and with HOXA11 (amino acids 1–281) or HOXA9 (amino acids 1–245). A bait containing full-length
MEIS1A,aknownco-factoroftheseHOXproteins,interactedwitheachHOXpreytested.Interactionsdonotoccurwiththecontrolbaitproteins,includingtheLexA
DBDalone,theBicoidhomeodomain(HD)orTGFbR1,showingthattheinteractionswithHOXA13andHOXD13arespecific.Positiveinteractionsarereportedas
‘+++’ and no observed interaction as ‘   ’.
Figure 2. HOXA13 interacts with the C-terminal MH2 domain of Smad5.
InteractionwastestedbetweenabaitmoleculeincludingHOXA13aminoacids
150–360 and prey molecules containing truncated Smad5 peptides. HOXA13
specifically interacted with all tested Smad5 preys containing the C-terminal
MH2 domain (146–465, 202–465 and 265–465). Preys without the MH2
domain failed to interact.
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(Figure 4). C3H 10T1/2 embryonic ﬁbroblast cells were
transfected with expression vectors for the constitutively
activated BMP receptor ALK3 and HOXD13 with or without
co-expression of N-terminal FLAG-epitope-tagged Smad1.
Using anti-FLAG antibody, HOXD13 was recovered
only in co-immunoprecipitations when FLAG-Smad1 was
co-expressed (Figure 4, lane 6). These results demonstrate
association in vivo of a paralog group 13 HOX protein
and receptor-regulated Smads, consistent with the yeast
two-hybrid results.
HOX group 13 proteins antagonize TGF-b1-stimulated
transcriptional activation
To determine whether group 13 HOX expression has a
molecular effect on Smad-mediated signal transduction, we
utilized the 3TP-Lux chimeric reporter that contains upstream
Smad binding elements from the human collagenase and
PAI-1 genes (35). This reporter has been demonstrated to
be activated by TGF-b stimulation in cells, including
Mv1Lu, through Smads (32,37,39,43,44) and has been useful
to demonstrate the consequences of co-expression of Smad-
interacting proteins on reporter activity (45). Here, we
expressed HOXA13, HOXD13 or HOXD13
IQN>AAA in cells
alongwiththe 3TP-Luxreporter (Figure5).Luciferaseactivity
measurements were taken for cells treated with vehicle or
TGF-b1 and compared with cells transfected with empty
vector. Comparable levels of protein expression of
HOXA13, HOXD13 and HOXD13
IQN>AAA were observed
in duplicate transfections via western analysis comparing
equal amounts of cellular protein (data not shown).
TGF-b1 stimulated 3TP-Lux reporter expression an average
of 6.3-fold (Figure 5), which is comparable with previous
Figure 3. Paraloggroup13HOXproteinsinteractwithMH2domainsofBMPandTGF-b/Activin-regulatedSmadproteins.(A)Neighbor-joiningtreegeneratedby
CLUSTALWforMusmusculusSmadproteinsandtheDrosophilaorthologsMadandMedea.ThosedemonstratedtointeractwithHOXA13(aminoacids150–360)
are shown in green italics, no interaction (Smad4) in red and not tested (no color). (B) Amino acid identity to the Smad5 C-terminal region, containing the MH2
domain and ability to interact with HOXA13 and HOXD13. ND, interaction potential was not determined.
Figure 4. HOXD13 and Smad1 interact in mammalian cells.
Co-immunoprecipitation demonstrates an in vivo interaction between both
full-length Smad1 and HOXD13. The constitutively active (CA) BMP type
IA receptor(ALK3)andHOXD13were expressedin C3H10T1/2cells withor
without co-expression of FLAG-Smad1. Whole cell lysates were prepared and
subjected to immunoprecipitation using an anti-FLAG agarose conjugate. Cell
lysates (lanes 1–3) and proteins eluted from the agarose conjugate (lanes 4–6)
wereresolvedbySDS–PAGEandsubjectedtowesternblottingseparatelywith
anti-HOXD13, anti-FLAG and anti-Smad1 antibodies. Lanes 3 and 6 are from
cellstransfectedwithCA-ALK3,HOXD13andFLAG-Smad1expressioncon-
structs, and lanes 1, 2, 4 and 5 from cells transfected with CA-ALK3 and
HOXD13 expression constructs. HOXD13 co-immunoprecipitated with
FLAG-Smad1 in the absence of co-transfected CA-ALK3 as well (data not
shown).
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Co-expression of HOXA13 and HOXD13 reproducibly
repressed reporter activation (down from 6.3-fold to 2.75-
and 3.1-fold, respectively). To determine whether HOX
monomeric DNA-binding capability is necessary for repres-
sion, we analyzed the effect of the HOXD13 DNA-binding
mutant protein HOXD13
IQN>AAA (46,47). In this protein, the
homeodomain residues I
47,Q
50 and N
51 are converted to alan-
ine residues. This mutant protein was able to comparably
repress TGF-b1-stimulated activation of the reporter (down
to 2.2-fold). This work shows that paralog group 13 HOX
proteins antagonize TGF-b1-stimulated gene expression,
presumably through interaction with endogenous Smads,
and this effect does not require HOX DNA-binding. In addi-
tion, we can conclude that the repression of luciferase reporter
expression is not likely through binding of HOX proteins to
the 3TP-Lux promoter or vector DNA.
HOX group 13 proteins antagonize Smad-mediated
transcriptional activation
We next wanted to test whether HOX group 13 proteins could
interfere with Smad-mediated transcriptional activation of the
pTRS6-E1b-luc reporter and to show conclusively in another
promoter reporter whether monomeric DNA-binding capabil-
ity by HOX group 13 proteins is critical for downregulation of
Smad-mediated transcriptional activation. The pTRS6-E1b
promoter is composed of six copies of the  732/ 721 seg-
ment of the human PAI-1 promoter that has been shown to
bind a TGF-b1-inducible protein complex, including Smad3
and Smad4 (34) upstream of the E1bTATA box in pE1b-luc.
The MH1 domain of Smad3 and full-length Smad4 bind the
12 bp TRS element, which is necessary and sufﬁcient for
Smad binding and for TGF-b1-stimulated expression. In
co-transfected Hep3B cells HOXA13, HOXD13 and
HOXD13
IQN>AAA reduced TGF-b1-stimulated expression 5-
fold, whereas the negative controls (PAI-RBP1 and AUF1) did
not affect the expression (Figure 6). HOXA9 was tested for the
ability to repress stimulation since it is known to bind to
Smad4, but not Smad3 (48). HOXA9 also reduced Smad-
mediated transcriptional activation, suggesting that not only
can Smad4 bind to HOXA9 and relieve HOXA9 DNA binding
and transcriptional repression (48), but HOXA9 can interfere
with Smad-mediated activation of transcription.
HOX group 13 proteins antagonize Smad3-MH2
domain-mediated transcriptional activation
The inhibitory effect of HOX group 13 proteins on Smad-
mediated activation of pTRS6-E1b-luc expression could
occur through several mechanisms and is complicated by
the interactions that occur between the MH1 and MH2
domains of Smads (49). To test whether HOX group 13
proteins could inhibit activation functions of the Smad3
MH2 domain, we used a mammalian one-hybrid approach.
GAL4-Smad3C protein, which substitutes the GAL4 DBD
for the MH1 domain of Smad3, reproducibly stimulated
expression on a GAL4 luciferase reporter, pG5B (Figure 7,
left). Co-transfection with HOXA13, by comparison with the
pCMV5 empty vector, reduces the expression 5-fold. Similar
repression is observed despite incubation with TGF-b1 (data
not shown). Activation was also reduced 2.4-fold by HOXD13
and HOXD13
IQN>AAA, but was unaffected by PAI-RBP1
(data not shown). HOXA13 did not repress the activation
of pG5B expression by GAL4-VP16 (Figure 7, right).
Figure 6. HOX proteins repress Smad-mediated transcriptional activation.
Hep3B cells in 6- or 12-well plates were co-transfected with TRS6E1b-luc
reporter construct (500 ng/well of 12-well plate) and control (pCMV5),
HOX, or negative control construct as indicated (500 ng). Renilla luciferase
(4ng)orb-galactosidase(40ng)vectorwasincludedtocorrectfortransfection
efficiency. Sixteen hours after transfection TGF-b (50 pM) or vehicle was
added and incubation continued for 24 h. Cells were harvested in cell lysis
buffer (Promega) and assayed for luciferase activity. For each sample, lucifer-
ase activity was normalized to the activity of transfection controls and fold
stimulationbyTGF-b determined.TGF-binductionin control wassetat 100%
andinductioninthepresenceofeachtestplasmidisexpressedasapercentageof
that in control. Triplicate samples were done in each experiment. The average
TGF-b induction from four experiments was 14-fold. Data are taken from 2–4
experiments for HOX constructs and a single experiment for the negative
controls.
Figure 5. HOX group 13 proteins antagonize TGF-b-stimulated 3TP-Lux
reporter activation. The effect of paralog group 13 HOX protein expression
on fold stimulation provided by TGF-b1 stimulation was compared with
empty vectorcontrol.Luciferaseexpressionwasconsistentlyrepressedin cells
expressing HOXA13, HOXD13 or the DNA-binding mutant HOXD13
(HOXD13
IQN>AAA).Asteriskindicatesthattheexperimentwasonlyperformed
once in duplicate.
4480 Nucleic Acids Research, 2005, Vol. 33, No. 14While it is theoretically possible that VP16 is strong enough to
overcome repression by HOXA13, the data indicate that group
13 HOX proteins are capable of speciﬁcally inhibiting the
transactivation functions of the Smad3 MH2 domain.
DISCUSSION
HOX/Smad interactions
To identify novel protein interactors of HOXA13, we created
and screened a limb bud cDNA library using yeast two-hybrid
analysis. We focused our attention on the speciﬁc interaction
between HOXA13 and Smad5.
We showed that interaction of the Smad5 MH2 domain with
paralog group 13 proteins was not a general property shared by
the AbdB-like HOX proteins HOXA11 or HOXA9, although
future exploration of the potential for interaction with HOX
groups 10 and 12 proteins would test the hypothesis that
Smad5 MH2 interaction is speciﬁc to group 13. We also
mapped the interaction to the MH2 Smad domain, showed
that Smad 1 and 2, but not Smad4, also interact with
HOXA13 and demonstrated a negative effect of HOXA13
on TGF-b-stimulated promoter activation, Smad3/Smad4-
activated promoter function and Smad3-C-terminus activation
function. While the data indicate that one function of the
HOXA13/Smad5 interaction may be to negatively modulate
Smad transcriptional activation function, cellular and gene
contexts may determine whether HOXA13/Smad5 interac-
tions result in repression or activation.
Smad1, a BMP-regulated Smad, interacts with HOXC8 (41)
disrupting HOX DNA binding, and thereby repression of gene
expression (40). Two HOXC8 interaction domains were found
in Smad1 (HID1 and HID2) that reside in the MH1 and linker
regions. In our studies, HOXA13 did not interact with the
homologous HID1/HID2 regions of Smad5 but rather with
the C-terminus that contains the highly conserved MH2
domain. The MH2 domain of Smad proteins is well known
for protein–protein interactions (23), yet this is the ﬁrst report
demonstrating an interaction between HOX proteins and the
MH2 domain of Smad proteins. In Smad proteins, the MH1
domains bind to DNA and both MH1 and MH2 domains bind
numerous proteins (24). The MH2 domain is capable of bind-
ing to transcriptional co-activators and is capable of activating
transcription in heterologous contexts. However, Smad pro-
teins may transcriptionally activate one promoter while
repressing another in the same cell type depending on gene-
speciﬁc co-factor complexes. Thus, one hypothesis is that
HOX group 13 proteins repress Smad transcriptional activa-
tion by direct binding to the activation motif, presumably
interfering with recruitment of co-activators or with Smad
interaction with the basal transcription complex. Interestingly,
Smad protein MH2 transactivation functions can occur
through CBP/p300, which has also been shown to interact
with HOX proteins (50). The prospect of a ternary complex
of Smads/HOX/CBP at promoters seems plausible. Conceiv-
ably, HOX group 13 proteins could interfere with Smad/CBP
interaction by binding to the MH2 domain with the Smad
protein on or off of DNA. Perhaps HOXA13 binds to both
proteins at promoters. Further studies are needed to determine
the mechanism of HOXA13 repression of Smad-mediated
activation and to deﬁne the Smad and HOX peptide sequences
necessary for interaction. For example, do HOX proteins asso-
ciate with R-Smad/Smad4 complexes after translocation to the
nucleus or can association occur in the cytoplasm? Does asso-
ciation with HOX proteins pull R-Smads off of DNA or lead to
R-Smad/Smad4 dissociation in solution?
HOXA13 and HOXD13 also interact with the MH2
domains of Smad1, another BMP-regulated Smad, Smad2, a
mediator of TGF-b/Activin signaling, and interfere speciﬁc-
ally with Smad3 C-terminal domain transactivation function.
These results indicate that the functional interactions with
Smads that are possible in tissues where group 13 HOX pro-
teins are expressedare potentiallyquitebroad.Weshowedthat
the group 13 HOX proteins were unable to interact with the
common Smad heterodimerization partner, Smad4. This lack
of interaction is consistent with the lower sequence identity to
the Smad5 C-terminal region for Smad4 (46.3%) compared
with Smad1 (97.5%), Smad2 (78.6%) and Smad3 (78.1%).
Even though HOXA13 and HOXD13 were able to interact
with Smad5 amino acids 175–465, more anterior AbdB-like
HOX proteins HOXA9 and HOXA11 could not. This is dis-
tinctly different from HOXA9, which binds to Smad4 (48) but
not to Smad5 (our study), Smad2 or Smad3 (48). We did not
test a group 12 HOX protein; however, paralog-speciﬁc inter-
actions on DNA have been described for other HOX co-factors
includingPBX(HOXproteins1–10)andMEIS(HOXproteins
9–13) (16,19,51,52). It seems likely that the association of
HOX proteins with Smads is very broad, which might be
anticipated. Target gene regulation has been demonstrated
through combinatorial interactions between HOX proteins
and the TGF-b signaling pathway effector Mad (Smad
ortholog) in Drosophila (53), suggesting the potential for
conservation, expansion and evolution of selectivity of the
Figure 7. HOXproteinsrepressSmad3-MH2domain-mediatedtranscriptional
activation. Hep3B cells in 12 well plates were co-transfected with pG5B-Luc
reporterconstruct(500ng),GAL4-Smad3C(left)orGAL4-VP16(right)fusion
protein construct (10 ng) with or without HOXA13 construct. b-galactosidase
(40 ng) vector was included to correct for transfection efficiency. Experiments
werecarriedoutasdescribedinthelegendtoFigure3,andluciferaseactivityin
each sample was normalized to b-galactosidase activity; the average of two
experiments is shown.
Nucleic Acids Research, 2005, Vol. 33, No. 14 4481interactions as a result of gene and cluster duplication.
Paralog-speciﬁc Smad interactions could be one way to
modulate the in vivo functional speciﬁcity of Hox genes,
and the potentially wide-ranging, yet selective, interactions
may constitute a Hox/Smad code.
We also showed that monomeric DNA-binding capability,
via experimental utilization of the HOXD13
IQN>AAA mutant
protein, is not necessary for the repression of TGF-b1- or
Smad-stimulated promoter activity. Interestingly, Smad1 ant-
agonizes the repressive effects of HOXC8 on the regulation of
reporter vectors containing the osteoprotegrin and osteopontin
promoters by displacing HOXC8 (40,41,54) and Smad4 inter-
feres with the ability of HOXA9 or HOXC8 to bind DNA and
repress the expression of the osteopontin promoter (48). In
contrast, repression of Smad activation of gene expression by
HOX group 13 proteins is mediated without HOX monomeric
DNA-binding capability. A similar mechanism has been
observed before for transcriptional activators whose physical
binding and mutual antagonism leads to the repression of
transcription and has been described for GR and AP1 (55),
GR and NFk-B (56,57), GR and NFGI-B (58), Tpit and SF-1
(59), Pitx1 and IRF3 or IRF7 (60) and for the homeodomain-
containing protein Pit1 and Gata2 (61). In the latter two cases,
disruption of the ability of the homeodomain to bind to DNA
did not interfere with binding to the other factors or transre-
pression. Our studies suggest that HOX and Smad proteins
might reciprocally antagonize their ability to regulate gene
expression. This may represent a more common in vivo
theme whereby HOX proteins regulate downstream gene
expression.
In what cellular contexts might HOXA13
and Smad5 function together?
Further work outside of the scope of this study is needed to
determine the in vivo cellular context(s) for which HOX A13/
D13/R-Smad interactions are important. The developing limb
bud is a logical site to examine and a potential genetic inter-
action might be tested in crosses of appropriate Smad mouse
mutants to those of Hoxa13 and/or Hoxd13. BMP and TGF-b-
signaling is important to several aspects of limb development,
including outgrowth (62), cartilage formation and differenti-
ation (63–66), digit identity (67), interdigital mesenchyme
apoptosis (65,66,68) and cessation of outgrowth (69).
However, Hoxa13 is also expressed in the caudal reproduct-
ive, genitourinary and digestive tracts, prostate, umbilical vas-
culature, allantois, migrating myoblasts and placenta
(12,15,70,71), among others. Moreover, Smad5 is also import-
ant for growth and differentiation of the vasculature of the
early embryo, including vessels in the limbs (26) and it is
highly expressed in the genitourinary tract (72). Importantly,
critical sites of Hoxa13 expression and function include the
umbilical artery (UA) (12,15) where HOXA13 deﬁciency
leads to umbilical artery stenosis and mutant fetal death at
midgestation. Stadler et al. (12) showed that UA walls of
Hoxa13
 /  embryos fail to organize appropriate cellular
boundaries between the endothelium and the mesenchyme.
The loss of ephrin ligand and receptor expression in both
the limbs and UA results was associated with a loss of cellular
adhesion and subsequently to the failure to form proper cell
boundaries. Hoxa13 mutants also exhibit defective growth of
the genital bud (9,13,15). Hypospadias may occur in humans
with HFGS secondary to mutations in HOXA13 (4), and in
Hoxa13 mutant mice hypospadias is associated with reduction
of Bmp signaling (13). Capillary vessels in the developing
glans penis or clitoris of mutant mice are abnormally enlarged,
which are highly reminiscent of the vascular phenotypes of
Smad5, Bmp4, Tgfb-1 and Tgfb receptor II knockout mice
(26,72–75). Hoxa13 loss, other than reducing Bmp signaling,
may also alter Smad activity via deﬁcient HOXA13/Smad
protein interactions in these structures. HOXA13/Smad inter-
action may also be important in the proper development of the
vasculature of the UA.
There is a growing list of co-factors that have been shown
to interact with HOX proteins. For the AbdB-like proteins,
genetic and physical interactions have recently been
identiﬁed between Gli3 and HOXD12 in the limb bud (76),
and in vitro interactions have been demonstrated between
HOXD13 and both CBP and Gli3 (50,76). In this context, it
is noteworthy that interactions have been reported between
Smads 1, 2, 3 and 4 and C-terminally truncated forms of
Gli3 (77). Thus, there appears to be the potential for higher
order complexes of potentially different kinds involving
GLI3/SMAD/HOX/CBP/MEIS/PBX proteins or, at the very
least, a dynamic equilibrium in vivo that may modulate their
respective activities in tissues where they are co-expressed.
Finally, our data also adds further support to the role of HOX
protein functions that do not require monomeric DNA-binding
capability, and future work will be needed to more fully
understand the scope of this mode of HOX function.
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